@article {Sramek:1 February 1999:1173-2563:137,
	author = "Sramek J.J.",
	author = "Hussey E.K.",
	author = "Clements B.",
	author = "Cutler N.R.",
	title = "Oral Sumatriptan Pharmacokinetics in the Migraine State",
	journal = "Clinical Drug Investigation",
	volume = "17",
	year = "1 February 1999",
	abstract = "<B>Objective:</B> This double-blind, parallel, multicentre study investigated the effect of migraine on absorption of oral sumatriptan (25, 50 and 100mg) compared with placebo.<P></P><B>Design:</B> Patients received sumatriptan or placebo in the clinic during an acute migraine and at least 7 days later, when pain-free. Pharmacokinetic and efficacy (n = 192) and safety (n = 259) parameters were assessed for 4 hours after administration of study medication.<P></P><B>Results:</B> Absorption of sumatriptan from 50 and 100mg tablets was not significantly different between the migraine and pain-free periods. There was however a statistically significant decrease (approximately 23&#037;) and delay (35 minutes) in absorption of sumatriptan from the 25mg tablet during a migraine compared with the pain-free period. Sumatriptan pharmacokinetics exhibited dose proportionality during the migraine and pain-free periods. All doses of sumatriptan were significantly superior to placebo in reducing headache pain. Adverse events were comparable among the sumatriptan groups and placebo group.<P></P><B>Conclusions:</B> Absorption of sumatriptan, administered at therapeutic doses, was not statistically significantly impaired during migraine versus the pain-free state. These data suggest that coadministration of drugs that improve the absorption of sumatriptan is not necessary during sumatriptan treatment.",
	pages = "137-144(8)",
	url = "http://www.ingentaconnect.com/content/adis/cdi/1999/00000017/00000002/art00008"
}